Immunome Raises $27M Via Private Equity Placement At 9%

by Vandana Singh, Benzinga Editor

April 26, 2021 8:37 AM | 1 min read | Make a Comment

In addition to encouraging preclinical data from the COVID-19 antibody cocktail announced today, Immunome Inc IMNM has entered into a private placement agreement of approximately $27 million with the sale of 1 million units at $27 per unit.
The offer price is at a 9% discount to Friday's closing price of $29.55.
Each unit consists of one IMNM common share and a warrant to purchase one-half of a common share at an exercise price of $45.
Immunome intends to use the net proceeds to accelerate the development of its oncology and infectious disease portfolio, including COVID-19, and for other general corporate purposes.
Price Action: IMNM shares are trading 8.7% higher at $32.12 in the premarket session on the last check Monday.

Posted In: Biotech News Health Care Offerings Small Cap General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.